Andrea Knapp

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.

W. Klapper, C. Burton, L. Sehn, 2021, Blood advances.

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

M. Dyer, P. Marlton, M. Dreyling, 2016, Haematologica.

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study

Junmin Li, Tongyu Lin, Andrea Knapp, 2021, Chinese medical journal.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

J. Gribben, G. Salles, L. Sehn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma

L. Sehn, F. Peale, M. Oestergaard, 2020, Leukemia & lymphoma.